Phase II Clinical Trial Evaluating the Efficacy and Safety of TQB2102 for Injection in Combination With Benmelstobart/Penpulimab With or Without Capecitabine in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic HER2-Positive Gastroesophageal Adenocarcinoma
Latest Information Update: 16 Jan 2025
Price :
$35 *
At a glance
- Drugs Benmelstobart (Primary) ; Penpulimab (Primary) ; TQB 2102 (Primary) ; Capecitabine
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group; Nanjing Shunxin Pharmaceutical
- 16 Jan 2025 New trial record